Neurogene Inc [NGNE] stock is trading at $19.37, up 27.27%. An important factor to consider is whether the stock is rising or falling in short-term value. The NGNE shares have gain 29.13% over the last week, with a monthly amount glided 70.51%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neurogene Inc [NASDAQ: NGNE] stock has seen the most recent analyst activity on June 27, 2024, when BMO Capital Markets initiated its Outperform rating and assigned the stock a price target of $65. Previously, Robert W. Baird started tracking the stock with Outperform rating on June 11, 2024, and set its price target to $54. On April 29, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $46 on the stock. William Blair started tracking the stock assigning a Outperform rating and suggested a price target of $61 on March 21, 2024. H.C. Wainwright initiated its recommendation with a Buy and recommended $45 as its price target on January 08, 2024. Stifel started tracking with a Buy rating for this stock on January 05, 2024, and assigned it a price target of $31. In a note dated January 04, 2024, TD Cowen initiated an Outperform rating.
Neurogene Inc [NGNE] stock has fluctuated between $6.88 and $74.49 over the past year. Currently, Wall Street analysts expect the stock to reach $37.5 within the next 12 months. Neurogene Inc [NASDAQ: NGNE] shares were valued at $19.37 at the most recent close of the market. An investor can expect a potential return of 93.6% based on the average NGNE price forecast.
Analyzing the NGNE fundamentals
Gross Profit Margin for this corporation currently stands at -16.02% with Operating Profit Margin at -97.02%, Pretax Profit Margin comes in at -87.43%, and Net Profit Margin reading is -87.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.36 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.31 points at the first support level, and at 13.25 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.97, and for the 2nd resistance point, it is at 22.57.
Ratios To Look Out For
For context, Neurogene Inc’s Current Ratio is 21.03. On the other hand, the Quick Ratio is 21.03, and the Cash Ratio is 5.02. Considering the valuation of this stock, the price to sales ratio is 297.05, the price to book ratio is 0.99.
Transactions by insiders
Recent insider trading involved Cobb Stuart, Chief Scientific Officer, that happened on May 14 ’25 when 6797.0 shares were sold. Officer, STUART COBB completed a deal on May 14 ’25 to buy 6797.0 shares. Meanwhile, President and CFO Cvijic Christine Mikail sold 4501.0 shares on Mar 13 ’25.
